Incyte Corp was incorporated in Delaware in 1991. It is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology. Its pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company faces competition from organizations, particularly fully integrated pharmaceutical companies that are pursuing pharmaceuticals that are competitive with JAKAFI and its drug candidates. Its trademaks include Incyte and JAKAFI. The Company's ongoing research and development activities and any manufacturing and marketing of JAKAFI and its drug candidates are subject to extensive regulation by numerous governmental authorities in the United States and other countries.